396 related articles for article (PubMed ID: 18000304)
41. [The effect of ferric ion on the differentiation of osteoclast and bone resorption].
Jia P; He YF; Gao C; Du HB; Hu ZY; Feng XQ; Li BY; Zhang ZL; Xu YJ; Lin H
Zhonghua Yi Xue Za Zhi; 2012 Aug; 92(31):2214-8. PubMed ID: 23158430
[TBL] [Abstract][Full Text] [Related]
42. Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro.
Spencer GJ; Utting JC; Etheridge SL; Arnett TR; Genever PG
J Cell Sci; 2006 Apr; 119(Pt 7):1283-96. PubMed ID: 16522681
[TBL] [Abstract][Full Text] [Related]
43. Interleukin-4 directly inhibits tumor necrosis factor-alpha-mediated osteoclast formation in mouse bone marrow macrophages.
Kitaura H; Nagata N; Fujimura Y; Hotokezaka H; Tatamiya M; Nakao N; Yoshida N; Nakayama K
Immunol Lett; 2003 Sep; 88(3):193-8. PubMed ID: 12941478
[TBL] [Abstract][Full Text] [Related]
44. Apolipoprotein E inhibits osteoclast differentiation via regulation of c-Fos, NFATc1 and NF-κB.
Kim WS; Kim HJ; Lee ZH; Lee Y; Kim HH
Exp Cell Res; 2013 Feb; 319(4):436-46. PubMed ID: 23246654
[TBL] [Abstract][Full Text] [Related]
45. Enhancement of RANKL-induced MITF-E expression and osteoclastogenesis by TGF-β.
Asai K; Funaba M; Murakami M
Cell Biochem Funct; 2014 Jul; 32(5):401-9. PubMed ID: 24519885
[TBL] [Abstract][Full Text] [Related]
46. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation.
Lee SK; Lorenzo JA
Endocrinology; 1999 Aug; 140(8):3552-61. PubMed ID: 10433211
[TBL] [Abstract][Full Text] [Related]
47. SC-19220, antagonist of prostaglandin E2 receptor EP1, inhibits osteoclastogenesis by RANKL.
Tsujisawa T; Inoue H; Nishihara T
J Bone Miner Res; 2005 Jan; 20(1):15-22. PubMed ID: 15619665
[TBL] [Abstract][Full Text] [Related]
48. Androgens suppress osteoclast formation induced by RANKL and macrophage-colony stimulating factor.
Huber DM; Bendixen AC; Pathrose P; Srivastava S; Dienger KM; Shevde NK; Pike JW
Endocrinology; 2001 Sep; 142(9):3800-8. PubMed ID: 11517156
[TBL] [Abstract][Full Text] [Related]
49. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
Valverde P; Tu Q; Chen J
J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
[TBL] [Abstract][Full Text] [Related]
50. Interleukin (IL)-12 mediates the anti-osteoclastogenic activity of CpG-oligodeoxynucleotides.
Amcheslavsky A; Bar-Shavit Z
J Cell Physiol; 2006 Apr; 207(1):244-50. PubMed ID: 16402377
[TBL] [Abstract][Full Text] [Related]
51. Anti-c-Fms antibody inhibits lipopolysaccharide-induced osteoclastogenesis in vivo.
Kimura K; Kitaura H; Fujii T; Hakami ZW; Takano-Yamamoto T
FEMS Immunol Med Microbiol; 2012 Mar; 64(2):219-27. PubMed ID: 22067001
[TBL] [Abstract][Full Text] [Related]
52. Tyrosines 559 and 807 in the cytoplasmic tail of the macrophage colony-stimulating factor receptor play distinct roles in osteoclast differentiation and function.
Feng X; Takeshita S; Namba N; Wei S; Teitelbaum SL; Ross FP
Endocrinology; 2002 Dec; 143(12):4868-74. PubMed ID: 12446614
[TBL] [Abstract][Full Text] [Related]
53. Estrogen inhibition of PTH-stimulated osteoclast formation and attachment in vitro: involvement of both PKA and PKC.
Liu BY; Wu PW; Bringhurst FR; Wang JT
Endocrinology; 2002 Feb; 143(2):627-35. PubMed ID: 11796519
[TBL] [Abstract][Full Text] [Related]
54. Decoy receptor 3 (DcR3) induces osteoclast formation from monocyte/macrophage lineage precursor cells.
Yang CR; Wang JH; Hsieh SL; Wang SM; Hsu TL; Lin WW
Cell Death Differ; 2004 Jul; 11 Suppl 1():S97-107. PubMed ID: 15002040
[TBL] [Abstract][Full Text] [Related]
55. The microphthalmia transcription factor regulates expression of the tartrate-resistant acid phosphatase gene during terminal differentiation of osteoclasts.
Luchin A; Purdom G; Murphy K; Clark MY; Angel N; Cassady AI; Hume DA; Ostrowski MC
J Bone Miner Res; 2000 Mar; 15(3):451-60. PubMed ID: 10750559
[TBL] [Abstract][Full Text] [Related]
56. Gymnasterkoreayne F inhibits osteoclast formation by suppressing NFATc1 and DC-STAMP expression.
Kim HJ; Hong J; Jung JW; Kim TH; Kim JA; Kim YH; Kim SY
Int Immunopharmacol; 2010 Nov; 10(11):1440-7. PubMed ID: 20831919
[TBL] [Abstract][Full Text] [Related]
57. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
58. The immunosuppressant rapamycin, alone or with transforming growth factor-beta, enhances osteoclast differentiation of RAW264.7 monocyte-macrophage cells in the presence of RANK-ligand.
Shui C; Riggs BL; Khosla S
Calcif Tissue Int; 2002 Nov; 71(5):437-46. PubMed ID: 12202955
[TBL] [Abstract][Full Text] [Related]
59. Self-assembled RANK induces osteoclastogenesis ligand-independently.
Kanazawa K; Kudo A
J Bone Miner Res; 2005 Nov; 20(11):2053-60. PubMed ID: 16234979
[TBL] [Abstract][Full Text] [Related]
60. Interleukin-33, a target of parathyroid hormone and oncostatin m, increases osteoblastic matrix mineral deposition and inhibits osteoclast formation in vitro.
Saleh H; Eeles D; Hodge JM; Nicholson GC; Gu R; Pompolo S; Gillespie MT; Quinn JM
Endocrinology; 2011 May; 152(5):1911-22. PubMed ID: 21363931
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
